FIELD: chemistry.
SUBSTANCE: invention relates to novel derivatives of formula I, as well as to pharmaceutical compositions based thereon
.
EFFECT: technical result is obtaining new compounds having agonistic activity on glucocorticoid or mineralocorticoid receptors, which can be used for treating disorders associated with modulation of glucocorticoid or mineralocorticoid receptor, for example, dry eyes.
10 cl, 3 tbl, 12 ex
Authors
Dates
2019-05-20—Published
2012-11-09—Filed